Iraklis C Mitsogiannis, Maria Mitsogianni, Maria Papathanassiou, Maria Anagnostou, Ioannis Tamposis, Lampros Mitrakas, Maria Samara, Vassilios Tzortzis, Panagiotis J Vlachostergios
{"title":"转移性肾细胞癌二线全身治疗的当前选择。","authors":"Iraklis C Mitsogiannis, Maria Mitsogianni, Maria Papathanassiou, Maria Anagnostou, Ioannis Tamposis, Lampros Mitrakas, Maria Samara, Vassilios Tzortzis, Panagiotis J Vlachostergios","doi":"10.15586/jkcvhl.v9i3.243","DOIUrl":null,"url":null,"abstract":"<p><p>Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). With current strategies of combining these two approaches in the front-line setting, less is known about optimal selection of therapy upon development of resistance in the second and later lines of treatment for progressive disease. This review discusses currently available therapeutic options in patients who have progressive RCC after prior treatment with double immune check-point inhibitors (ICIs) or ICI-TKI combinations.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":" ","pages":"29-40"},"PeriodicalIF":1.9000,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551369/pdf/","citationCount":"3","resultStr":"{\"title\":\"Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma.\",\"authors\":\"Iraklis C Mitsogiannis, Maria Mitsogianni, Maria Papathanassiou, Maria Anagnostou, Ioannis Tamposis, Lampros Mitrakas, Maria Samara, Vassilios Tzortzis, Panagiotis J Vlachostergios\",\"doi\":\"10.15586/jkcvhl.v9i3.243\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). With current strategies of combining these two approaches in the front-line setting, less is known about optimal selection of therapy upon development of resistance in the second and later lines of treatment for progressive disease. This review discusses currently available therapeutic options in patients who have progressive RCC after prior treatment with double immune check-point inhibitors (ICIs) or ICI-TKI combinations.</p>\",\"PeriodicalId\":44291,\"journal\":{\"name\":\"Journal of Kidney Cancer and VHL\",\"volume\":\" \",\"pages\":\"29-40\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551369/pdf/\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Kidney Cancer and VHL\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15586/jkcvhl.v9i3.243\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Kidney Cancer and VHL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15586/jkcvhl.v9i3.243","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma.
Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). With current strategies of combining these two approaches in the front-line setting, less is known about optimal selection of therapy upon development of resistance in the second and later lines of treatment for progressive disease. This review discusses currently available therapeutic options in patients who have progressive RCC after prior treatment with double immune check-point inhibitors (ICIs) or ICI-TKI combinations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
